FDA Approves SUFENTANIL CITRATE — Hospira, Inc.

FDA oncology advisory committee voted to recommend for approval Hospira Inc.’s generic version of the ultra-potent synthetic opioid sufentanil citrate for epidural use, a decision that is expected to shift revenue streams in the specialty pain management market and intensify competitive pricing pressures for branded alternatives.